RT Book, Section
A1 Murri, Nelda
A2 Brunton, Laurence L.
A2 Chabner, Bruce A.
A2 Knollmann, Björn C.
SR Print(0)
ID 1127872470
T1 The Goodman & Gilman Year in Review: 2011 New and Noteworthy FDA Approvals
T2 Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 12e
YR 2015
FD 2015
PB McGraw-Hill Education
PP New York, NY
SN 9780071624428
LK accessanesthesiology.mhmedical.com/content.aspx?aid=1127872470
RD 2023/09/28
AB The  FDA  approved  33  drugs  and  biologics  of  note  in  2011.  Most  are  pharmacologically  similar  to  others  already  marketed  (see  Table  71-2).  Among  the  remainder  are  18  "first-in-class"  agents  for  acute  coronary  syndrome,  angioedema,  chronic  obstructive  pulmonary  disease,  congenital  factor  XIII  deficiency,  depression,  head  lice,  hepatitis  C  infection,  lupus,  lymphoma,  melanoma,  myelofibrosis,  prostate  cancer,  seizures,  diagnosis  of  Parkinsonian  syndromes,  and  vaccination  of  military  personnel  against  adenovirus  (see  part  1  of  this  series).  Fourteen  of  the  new  drug  approvals  in  2011  were  granted  orphan  drug  status  for  rare  diseases  (see  Table  71-2,  Table  71-3,  and  part  1  of  this  series).  Two  of  the  new  drugs  (crizotinib  for  non-small  cell  lung  cancer  and  vemurafenib  for  melanoma)  were  approved  in  conjunction  with  diagnostic  genetic  tests  and  represent  a  breakthrough  in  the  field  of  personalized  medicine.1  In  addition,  one  new  approval,  HEMACORD  is  the  first  cord  blood  therapy  approved  in  the  US.2